Expression of PDZK1 in endometrial carcinoma and its clinical significance

Abstract

Objective To investigate the expression of PDZK1 in endometrial carcinoma and explore its correlation with the clinicopathological features of the patients. Methods RT-PCR, Western blotting and immunohistochemistry were used to detect the expression of PDZK1 at mRNA and protein levels in 53 specimens of endometrial carcinoma tissues and 32 normal endometrial specimens obtained in the First Affiliated Hospital from January 2012 to June 2017. Chi-square test, Kaplan-Meier analysis, and log-rank test were used to analyze the correlation of PDZK1 expression with the clinicopathological factors, disease-free survival (DFS), and overall survival (OS) time of the patients. Results The endometrial carcinoma tissues showed significantly higher expressions of PDZK1 than normal endometrial tissues at both the mRNA (2.415±0.663 vs 0.986±0.322, P 0.05). The patients with high PDZK1 expression had significantly shorter DFS (P < 0.05) and OS time (P < 0.05). Conclusion PDZK1 is highly expressed in endometrial carcinoma and associated with a poor tumor differentiation, an advanced FIGO stage, lymphatic metastasis and a poor prognosis of the patients, suggesting its value as a new biomarker as well as a therapeutic target of endometrial carcinoma.

Keywords

• pdzk1
• endometrial carcinoma
• clinicopathological factors